ACCME to guard names during C+I

The Board of the Accreditation Council for CME approved a new process for handling complaints on accredited providers, in which those that break the rules will not be identified unless changes in their accreditation status occur.

The approval was expected. Out of 50 responses received after a six-week comment period that ended in March, 80% favored confidentiality even after a violation is verified during the Complaints and Inquiries Process, used to investigate criticisms of activities such as commercial bias. The council also expects to issue a call for comment regarding providers' obligations to provide corrective information if an activity is found to be noncompliant.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.